Effects of Coadministration of Empagliflozin and Colchicine on Heart Failure.

Evaluation Effect of Empagliflozin and Colchicine on Quality of life in Heart Failure with Reduced Ejection Fraction: A Randomized Clinical Trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20111206008307N40

Enrollment

Registered

2022-11-05

Start date

2022-11-01

Completion date

Unknown

Last updated

2022-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart failure. Systolic (congestive) heart failure

Interventions

Intervention 1: Intervention group: Patients will receive 25 mg of empagliflozin daily for three months with standard treatments. Intervention 2: Control group: Patients will receive 10 mg empaglifloz

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Heart Failure with Reduced Ejection Fraction Aged 18 to 80 years Consented patients

Exclusion criteria

Exclusion criteria: Pregnancy Lactation Liver failure Kidney failure Systolic blood pressure less than 100 or more than 180 mm Hg Diabetes mellitus Malignancy

Design outcomes

Primary

Measure	Time frame
Quality of life score in KCCQ questionnaire. Timepoint: The beginning of the study and months 3 and 6. Method of measurement: KCCQ questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactTabriz University of Medical Sciences

Tabriz University of Medical Sciences

tentezari@gmail.com+98 912 635 0900

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026